Article Details

Verismo doses first subject in Phase I trial of SynKIR-310 - Clinical Trials Arena

Retrieved on: 2025-01-13 16:59:34

Tags for this article:

Click the tags to see associated articles and topics

Verismo doses first subject in Phase I trial of SynKIR-310 - Clinical Trials Arena. View article details on hiswai:

Excerpt

Data Insights. The gold standard of business intelligence. Find out more. Designed to assess the therapy's tolerability, preliminary ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up